Ram Mohan Jaiswal

Ram Mohan Jaiswal

Auto-generated profile, based on publicly available information

Ram Mohan Jaiswal

Department of Transfusion Medicine Mahatma Gandhi Medical College and Hospital Jaipur India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Open access
RJRam Jaiswal
Ram Jaiswal
SSShweta Sharma
Shweta Sharma
ASAshina Singla
Ashina Singla
NDNimisha Devpura
Nimisha Devpura
RVRajat Vohra
Rajat Vohra
RSRajendra Sureka
Rajendra Sureka
Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the causative agent of corona virus disease-2019(COVID- 19) which has led to a global pandemic. The true extent of the burden of COVID-19 may be underestimated, and there is need to know the current prevalence of SARS-CoV-2 antibody in population. The present study was a cross-sectional study to assess prevalence of SARS-CoV- 2 IgG antibody among 586 healthy voluntary blood donors who donated whole blood between mid-December 2020 to January 2021. A chemiluminescence assay was used to detect the presence of SARS-CoV-2 IgG antibody in serum samples in addition to recommended transfusion transmitted infections tests and Signal to Cut Off (S/C) > 1 was considered as reactive for antibody as per manufacturer’s instructions. In the present study, 586 healthy voluntary blood donors were enrolled and were screened for SARS- CoV-2 IgG antibody. Out of 586 donors, 52 donors had indeterminate values of SARS-CoV-2 IgG antibody. A total of 534 healthy voluntary blood donors’ samples were included in the present study for analysis. Out of total 534 healthy blood donors, 42.88% (229) were found to be seropositive while 57.11% (305) were found to be seronegative. A 43% positivity of SARS-CoV-2 IgG antibody among healthy blood donors was detected which is an indication of presence of infection at community level and majority of the population already has been exposed to SARS-CoV-2 infection. However, there was no statistically significant association of type of blood group and age with seropositivity.

3 September 2024 in HLA
Verified
Journal Article
Closed access
RJRam Mohan Jaiswal
Ram Mohan Jaiswal
SSShyam Swaroop
Shyam Swaroop
ASAshina Singla
Ashina Singla
SSShweta Sharma
Shweta Sharma
SGSuraj Godara
Suraj Godara

20 January 2022 in HLA
Verified
Journal Article
Closed access
PDF file
RJRam Mohan Jaiswal
Ram Mohan Jaiswal
UMA KANGAUMA KANGA
UMA KANGA
ASAshina Singla
Ashina Singla
SGSuraj Godara
Suraj Godara

16 December 2025 in Transfusion
Verified
Journal Article
Closed access
AJAikaj Jindal
Aikaj Jindal
JPJose Arnulfo Perez‐Carrillo
Jose Arnulfo Perez‐Carrillo
RDRounak Dubey
Rounak Dubey
RJR. M. Jaiswal
R. M. Jaiswal
DLDivjot Singh Lamba
Divjot Singh Lamba
RGRichard R. Gammon
Richard R. Gammon

1 July 2025 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Closed access
AMAditya A Mundra
Aditya A Mundra
AMAbha Mathur
Abha Mathur
RJRam Mohan Jaiswal
Ram Mohan Jaiswal
MVManeesh Vijayvargiya
Maneesh Vijayvargiya
NSNeha Sethi
Neha Sethi
SGShikha Goyal
Shikha Goyal
Introduction: Non-Small Cell Lung Cancers (NSCLC) is classified into squamous cell carcinoma and adenocarcinoma. Adenocarcinoma is commonly seen in non smoking females. Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase receptor which gets mutated in lung cancer. Tyrosine Kinase Inhibitors (TKI) like gefitinib are known to a have a good response in lung adenocarcinoma. Aim: The aim of this study was to detect EGFR mutations in NSCLC and associate the mutation status with clinicopathological parameters. Materials and Methods: The present cross-sectional study was conducted in the Department of Oncopathology and Transplant Immunology Molecular lab at Mahatma Gandhi Hospital, Jaipur, Rajasthan, India, from June 2023 to May 2024. All histopathological diagnosed cases of NSCLC were included in the study. Immunohistochemistry was further applied. EGFR mutation status (19Del, T790M, S768I, C797S, Ex20ins, G719X, L858R, L861Q) was checked using Real Time Polymerase Chain Reaction (PCR). An attempt was made to find out the association between the mutation status and various clinicopathological parameters. Statistical analysis was done using Statistical Package for Social Sciences (SPSS) statistics software windows version 22.0 released 2013. Results: A total of 37 cases were included in the study of which 21 were males and 16 were females. There was near equal distribution when a comparison of smoking status was done. The most common clinical symptom was cough and the most common histological type was acinar adenocarcinoma. Thirteen out of 37 cases showed EGFR mutations. Exon 19 deletion was the most common mutation. EGFR mutation status showed statistical significance with non smokers and acinar adenocarcinoma. Conclusion: Adenocarcinomas are more commonly seen in non smoking females. Exon 19 deletion is the most common type of EGFR mutation seen in lung adenocarcinomas. Mutations in EGFR are associated with good response to TKI.

31 July 2023 in Journal of South Asian Federation of Obstetrics and Gynaecology
Verified
Journal Article
Open access
SGSwati Garg
Swati Garg
USUrvashi Sharma
Urvashi Sharma
VPVidisha Payal
Vidisha Payal
RJRam Mohan Jaiswal
Ram Mohan Jaiswal